Compare Boston Scientific Corporation (BSX) vs Crown Castle International Corp (CCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Crown Castle International Corp — how do they compare? Boston Scientific Corporation trades at $43.3 (market cap $66.37B), while Crown Castle International Corp trades at $79.34 (market cap $34.50B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and Crown Castle International Corp pays a 5.38% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | CCI | |
|---|---|---|
Market Cap | $66.37B | $34.50B |
Sector | Health | Real Estate |
52-Week High | $108.14 | $113.91 |
52-Week Low | $42.63 | $74.92 |
Enterprise Value | $75.94B | $64.33B |
Dividend Yield | — | 5.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Crown Castle (CCI) trades at $79.84, up 0.23% on the day, with a bearish technical signal from moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates, but maintains strong profitability with a 73.82% gross margin. Recent news highlights its pure-play U.S. tower focus and upcoming Q2 2026 earnings call on July 22, 2026.
CCI presents a turnaround opportunity with analyst consensus targeting $97.33, implying 22% upside, but faces risks from high debt levels and volatile earnings. The stock's negative equity and bearish technicals warrant caution despite attractive dividend yield and cost reduction initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
